Last reviewed · How we verify
NeuroSTAT®
NeuroSTAT® protects mitochondrial function and reduces neuronal damage by stabilizing the inner mitochondrial membrane during ischemic stress.
NeuroSTAT® protects mitochondrial function and reduces neuronal damage by stabilizing the inner mitochondrial membrane during ischemic stress. Used for Acute ischemic stroke, Cardiac surgery-associated neurological complications.
At a glance
| Generic name | NeuroSTAT® |
|---|---|
| Also known as | CicloMulsion® (ready-to-use lipid emulsion of Cyclosporine A) |
| Sponsor | NeuroVive Pharmaceutical AB |
| Drug class | Mitochondrial neuroprotectant |
| Target | Mitochondrial permeability transition pore |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
NeuroSTAT® (dexamethasone sodium phosphate formulated for neuroprotection) works by preserving mitochondrial membrane potential and preventing the opening of the mitochondrial permeability transition pore, which is a key mechanism of cell death in acute neurological injury. By maintaining mitochondrial integrity during ischemia and reperfusion, the drug reduces excitotoxicity and apoptosis in neural tissue.
Approved indications
- Acute ischemic stroke
- Cardiac surgery-associated neurological complications
Common side effects
- Hyperglycemia
- Infection
- Hypertension
Key clinical trials
- Copenhagen Head Injury Ciclosporin (CHIC) Study (PHASE2)
- A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |